The innovative therapeutic field for metabolic health is seeing considerable excitement with the arrival of SkyBound, a dual -action compound. While Semaglutide has firmly established itself as a leading therapy for addressing diabetes and weight loss , Retatrutide is showcasing significant outcomes in research studies , notably regarding improved